[PDF] Top 20 B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Has 10000 "B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma" found on our website. Below are the top 20 most common "B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma".
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
... There was one grade 5 event during the study. Subject 08 (cohort 1) was a 71-year-old man with IgA lambda MM with com- plex karyotype. By the time of CART-BCMA infusion, he was pro- gressing rapidly through bridging ... See full document
13
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
... a myeloma-propagating phenotype (44, ...stem cells (43). In some human cancers, Sox2 defines a subset of cells with unique capacity to propagate malignancy ...stem cells) (59, ...cancer ... See full document
15
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
... CD4+ CAR-T cells ...CD4+ CAR-T secretion ...Granzyme B + MIP- 1α + polyfunctionality of donor ...CD8+ CAR-T cells of all 4 donors (Additional file ... See full document
16
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
... Chimeric antigen receptor (CAR) T cell therapy has emerged as an efficacious treatment in some relapsed/ refractory hematologic ...cancers. CAR T cell therapies have been ... See full document
8
Awakening immunity against cancer: a 2017 primer for clinicians
... rather T cell-centric; not just CAR T cells, but specific antigen- targeting T-cell receptor transduced T cells and tumor- infiltrating ... See full document
5
Rejection of Experimental Hodgkins Lymphoma by T Cells Engineered with a CD19 Chimeric Antigen Receptor
... 6% cells expressing CD34 as a marker of ...transduced cells in the total population by CD34 selec- tion improved levels of specific lysis (Figure ...CD34+ cells and level of specific ... See full document
9
Treatment of malignant pleural mesothelioma by fibroblast activation protein specific re directed T cells
... malignant cells [33], immunotherapy is a novel therapeutic strategy to fight MPM ...an active-specific immune re- ...directed T cells as a new option for treatment of ...tumor ... See full document
11
The roles of stem cell memory T cells in hematological malignancies
... histocompatibility antigen (MiHA)-specific CD8 + T cells had superior expansion capacity in vitro and induced superior antitumor activity in multiple myeloma-bearing ... See full document
5
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent
... temperature followed by Extravidin-Avidin conjugate (100 m l per well at 1:500 dilution in PBS/Tween for 1 hr) and substrate solution (Sigma, Dorset, UK) for approximately 30 minutes for development in the dark. Samples ... See full document
10
Chimeric antigen receptor T cell therapies for multiple myeloma
... LCAR-B38M CAR-T cells in the peripheral blood at 4 months, and only 5 patients showed CAR-T cells at 10 months after infusion ...anti-BCMA CAR-T ...abnormalities ... See full document
12
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... bispecific T cell engagers, and antibody- drug conjugates make the antibody-directed agents more powerful with less ...for T cells have led to the revolution of modern cancer ...immunotherapy. ... See full document
5
Chimeric antigen receptor T cell therapy for multiple myeloma
... MM-specific cell surface antigens. Since the search for genes and proteins specific- ally expressed in MM cells has already been carried out thoroughly all over the world, it seems to be ... See full document
5
Immunoregulatory T Cell Function in Multiple Myeloma
... Multiple myeloma is a malignancy characterized by uncontrolled monoclonal B cell differentiation and immunoglobulin ...mitogen-induced B cell differentiation assays, ... See full document
12
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
... chimeric antigen receptor (CAR) T cells, which have revolutionized the treat- ment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic ...of CAR ... See full document
12
Expression of BAFF receptors in muscle tissue of myositis patients with anti Jo 1 or anti Ro52/anti Ro60 autoantibodies
... exposure, B cells can differentiate into plasmablasts and increase their resistance to Fas-mediated apoptosis and promote survival ...dendritic cells (pDCs), together with the IFNα/β- inducible ... See full document
13
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
... of multiple myeloma burden and clinical responses to infusions of anti-BCMA CAR-T ...marrow cells were 25% plasma cells as shown by CD138 ...400). b Three months after ... See full document
9
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
... some specific populations of the immunosuppressive tumor- associated macrophages (TAMs) have emerged as a re- search hotspot ...HCC cells not only has a positive association with PD-L1 ex- pression in HCC, ... See full document
21
Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system
... CD19 CAR T cells pro- duced at our facility. CD19 + Raji cells (targets) were labeled with CellTrace Violet and co-cultured with CD19 CAR T cells (effectors) or ... See full document
14
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
... tumor cells. Ligation of PD-1 by either of its ligands downregulates T-cell receptor (TCR) signaling and abrogates stimulatory cytokine pro- duction ...effector T cells identifies ... See full document
9
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
... mmeso-CAR T cells, but combining Ad-mTNFa-mIL2 enables tumor ...mmeso-CAR T cells in combination with an adenovirus expressing murine TNF-α and murine IL-2 in immunocompetent ... See full document
18
Related subjects